Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for non-alcoholic fatty liver disease in obese adults
IRCT20210614051574N3Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pioglitazone in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Fatty liver grade. Started Sep 2021; status: completed.
02
Drugs
pioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20210614051574N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210614051574N3.